Fusion Pharmaceuticals Inc.
RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
Last updated:
Abstract:
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
Status:
Application
Type:
Utility
Filling date:
3 Dec 2019
Issue date:
24 Mar 2022